Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Teriflunomide in Subjects With Relapsing Multiple Sclerosis

Trial Profile

Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Teriflunomide in Subjects With Relapsing Multiple Sclerosis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Ponesimod (Primary) ; Teriflunomide
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms OPTIMUM
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 31 Mar 2017 Planned End Date changed from 1 Mar 2019 to 15 May 2019.
    • 31 Mar 2017 Planned primary completion date changed from 1 Feb 2019 to 17 Apr 2019.
    • 30 Mar 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top